

JAMILA

THERAPEUTICS AG

Extending the Life of Critical Therapies

COMPANY PRESENTATION

DISCLAIMER

This presentation and the information contained herein are confidential and the property of Jamila Therapeutics AG, Seefeldquai 1, 6318 Walchwil, Zug, Switzerland (“Jamila”, or the “Company”). This presentation is intended to introduce you to the Company. By attending this presentation or by accepting delivery of these materials, the recipient agrees not to reproduce, transmit, circulate or otherwise make available the materials to any other person outside of their company/organization without the prior written consent of the Company. Any dissemination of these materials without the prior written consent of may also result in violation of applicable laws and is therefore prohibited.

This presentation does not constitute an offer or invitation to subscribe for or purchase any securities and nothing contained herein shall form the basis of any contract or commitment whatsoever. This presentation does not purport to summarize all of the conditions, risks, and other attributes of an investment in the Company and is qualified in its entirety by the information, including information in the Data Room, to be made available by the Company to persons meeting certain investment criteria.

Certain statements contained in this presentation may be statements of future expectations and other forward-looking statements and involve known and unknown risks and uncertainties. Statements contained in this presentation regarding, or based on, past trends or activities should not be taken as a representation that such trends or activities will continue in the future. There is no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.

The distribution of this presentation in certain jurisdictions may be restricted by law and, accordingly, this presentation is being communicated only to persons who have requisite experience in matters relating to investments and are persons to whom it may be lawful to communicate it without contravention of any unfulfilled registration requirements or other legal restrictions in the jurisdiction in which they reside or conduct business or in which they receive this document (all such persons being referred to as relevant persons). This presentation is only directed at relevant persons and any investment or investment activity to which the presentation relates is only available to relevant persons or will be engaged in only with relevant persons. Solicitations resulting from this presentation will only be responded to if the person concerned is a relevant person. Other persons should not act upon this presentation or any of its contents. Any securities offered and sold in the United States will be so offered and sold in transactions exempt from registration under the US Securities Act of 1933 and only to persons who are qualified purchasers within the meaning of Section 2(a)(51) of the US Investment Company Act of 1940 or persons reasonably believed to be qualified institutional buyers or accredited investors as defined in Rule 144A and Rule 501, respectively, of the US Securities Act of 1933. The securities described herein will not be registered under the US Securities Act of 1933 or the securities laws of any state of the United States.

Investors and prospective investors in securities of the Company are required to make their own independent investigation and appraisal of the business and financial condition of the Company and the nature of the securities. Neither the Company, its affiliates, their respective directors, officers, employees or agents (the “Company Group”) gives any representation or warranty, express or implied, as to: (i) the achievement or reasonableness of future projections, management targets, estimates, prospects or returns contained in this document, if any; or (ii) the accuracy or completeness of any information contained in this document, any other written information or oral information provided in connection therewith or any data that any of them generates. Furthermore, and without prejudice to liability for fraud, no member of the Company Group accepts, or will accept any liability, responsibility or obligation (whether in contract, tort or otherwise) in relation to these matters. By reading this presentation or participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.

FOUNDED

2020

LOCATIONS

Switzerland HQ
United States
Brazil

About Jamila

*Extending the Life
of Critical Therapies*


Jamila Therapeutics AG is a privately owned global pharmaceutical company that aims to provide continued access to mature life changing therapies to patients around the world.

Our product portfolio is developed through acquiring licenses and marketing authorizations of drug products which are commonly divested by industry players.

We are continuously striving to offer a wide range of effective, high quality and affordable products in the areas of severe pathologies and rare & chronic diseases.

While we intend to revitalize brands in major markets, we also have an aggressive plan to invest further in emerging markets and low to middle income countries, which have rapidly growing middle classes, fast-growing and aging populations, rising chronic disease and a strong demand for recognized, quality medicines.

Jamila Approach





Our Purpose

Our purpose is to become a premiere, innovative and sustainable therapeutics provider that enables patient access to mature and essential products worldwide.

Our plan is to re-vitalize established brands with fresh digital approaches to help optimize the pharma ecosystem considering sustainability and agility in volatile market conditions, while ensuring supply continuity and affordability in Low & Middle-Income Countries.

Utilizing advanced digital technologies to enable high-quality sustainable operations, we can better support our patients, healthcare professionals and our partners to reduce cost, maintain compliance, and improve patient outcomes.



Jamila Advantage

Experience with World-Class Products & acquisitions
backed by Big Pharma partnerships

Our Advisory Board & Leadership team has in-depth
experience with leading pharmaceutical and biotechnology
companies such as:



JAMILA ADVANTAGE

Global Footprint

+ network of **185** partners worldwide
doing business in **27** countries and **14** languages

USA

Brazil

South Africa

(long term)

CH &
Europe

Global HQ
Switzerland

SE Asia

(long term)

JAMILA
THERAPEUTICS AG



Jamila Advantage

Competitive Pricing + Supply Chain Expertise =
Higher Gross Margins



Big Pharma Veterans + M&A experience =
Efficient Divestments



Regional Partnerships + Market Visibility =
International Footprint



Sustainable Lean Model + Speed to Market =
Seamless Integration



Traceability + Digital Integration =
Ecosystem Collaborations



Expertise

+150 Years of
Combined Experience




Corporate Development

Building a network of trusted partners who enable portfolio growth through product acquisitions, operational efficiency and organizational excellence.



Commercial Operations & Finance

Ensuring continuity of affordable product access while delivering top of the line growth and brand equity through international expansion, partnerships, and patient-centric technologies.



Pharmaceutical Operations

Ensuring compliant, high quality and affordable products are delivered to the market by working with our global Contract Manufacturing and Regulatory Service partners streamlining market authorization, technical transfers, capacity and improving KPI's through innovation.



Organizational Strategy & Program Management

Delivering sustainable value and critical expertise to the end business network supported by a structured and agile program management office.



Digital

Enabling new avenues of efficiency by addressing old challenges with emerging technologies while ensuring real-time visibility, security and quality to highly regulated and complex business operations.

Expanding Access

in Emerging and Low-Middle Income Countries



OUR LICENSING MODEL

- Governments, NGOs & Regional Healthcare Consortia
- Critical and Emergency Care products
- Transfer of manufacturing locally
- Online healthcare curriculum & local community partnerships

KEY PERFORMANCE INDICATORS

- Hybrid model: licensed, joint ventures, owned
- Scaled buy-in on governmental and industry levels
- Committed revenue share
- Naming & sponsorship packages

SOCIAL IMPACT

We are committed to delivering sustainable healthcare education and engagement initiatives that will accelerate innovation and diversity while empowering the world's untapped minds. Our aim is to consistently drive collaboration in order to find vital solutions that will continue to improve the well being of patients and people everywhere while supporting the revitalization of our planet.



EDUCATE & ENGAGE



INNOVATE & EMPOWER

Foundation elements that underpin our strategy to be a World Class brand

- A genuine & relentless passion for our customers, humanity and the planet
- First class Leadership Culture
- First class Marketing - engaging and cost efficient
- First class Recruitment & Coaching – Grade A talent want to join us for the greater purpose
- Technological Innovation - always exploring the game changers
- A passion & energy to evolve our vision, business model and revenues

JAMILA

THERAPEUTICS AG

Extending the Life of Critical Therapies

THANK YOU

For more information, visit us at www.jamilatherapeutics.com